Given the increased PD-1 levels on tumor-infiltrating CD8+ T cells following MNK inhibitor treatment, we evaluated whether cotreatment with an anti–PD-1 antibody could overcome T cell exhaustion and suppress tumor growth. This evidence concerns the gene CD8A and neoplasm.